Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia. Show more

Location: Level 9, 650 Chapel St, Melbourne, VIC, 3000, Australia | Website: https://opthea.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

583.1M

52 Wk Range

$3.03 - $6.30

Previous Close

$3.41

Open

$3.41

Volume

N/A

Day Range

$3.41 - $3.41

Enterprise Value

550.2M

Cash

48.44M

Avg Qtr Burn

-39.66M

Insider Ownership

0.00%

Institutional Own.

4.52%

Qtr Updated

06/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
OPT-302 Details Wet age-related macular degeneration , Eye disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OPT-302 Details Diabetes, Eye disease , Diabetic macular edema	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.